SeraCare Life Sciences, a provider of high-quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today announced the launch of its new ACCURUN® 501 C. difficile Control – the company's first molecular control product targeting hospital acquired infections.
ACCURUN 501 C. difficile Control is formulated for use with in vitro diagnostic tests that detect C. difficile DNA in human stool samples. Manufactured from cultured Clostridium bacteria of four different strains or species delivered in a set of four vials, the bacteria are inactivated and in a human synthetic stool matrix. The control is ready-to-use in assays that detect C. difficile DNA with any transport system.
"Hospital acquired infection assays present unique sample challenges which require dependable, whole cell controls. Our new ACCURUN® 501 product is a full process control that is intended to not only estimate laboratory testing performance but also immediately detect analytical errors and monitor the entire testing process. As a result, our customers have greater confidence in fulfilling their QC requirements," says Christopher Long, Product Manager at SeraCare.
SeraCare's new ACCURUN® 501 product is available immediately in the U.S. and internationally.
Gut bacteria manipulation may offer a promising approach to managing inflammatory bowel disease